Cullinan Oncology reports Q3 net loss of $39.2M; cash runway extends to H2 2026

Cullinan Therapeutics, Inc.

2023-Q3 EPS reported -$3.15

Cash and investments $481.9M at Sept 30, 2023; runway extended into H2 2026 from prior into 2026, driven by $38M ATM net proceeds and higher interest income.
Net loss $39.2M in Q3 vs $32.2M in Q2; R&D expenses $33.8M (up from $27.4M) on higher manufacturing and clinical costs.
CLN-619 (MICA/B) monotherapy clinical activity observed; combination dose escalation enrollment completed; initial data expected Q2 2024.
Zipalertinib (EGFR ex20ins) Phase 2b REZILIENT1 enrollment completion targeted by end 2024; Phase 3 REZILIENT3 initiated.
CLN-978 (CD19xCD3) first patient dosed in Phase 1 for R/R B-NHL; CLN-617 first-in-human expected by year-end 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cullinan Therapeutics, Inc. updated its third quarter ended September 30, 2023 guidance (reaffirmed).

Period: third quarter ended September 30, 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.